• FGFR1 as a Druggable Target in Schizophrenia: Insights from

  2026-07-17

  A comprehensive genomic and functional analysis has identified FGFR1 as a promising druggable gene for schizophrenia, leveraging Mendelian randomization, co-localization, and molecular docking techniques. This work advances the understanding of schizophrenia pathogenesis and highlights actionable targets for future therapeutic development.

• PD98059 in Precision Apoptosis and Hepatoprotection Research

  2026-07-16

  Discover how PD98059, a selective MEK inhibitor, enables advanced research in apoptosis modulation and hepatoprotection. This article uniquely examines its mechanistic role in mitochondrial apoptosis and oxidative stress, with direct protocol guidance and insights from recent in vivo studies.

• STMN2 Protein Depletion via Stress Granules in ALS Pathogene

  2026-07-16

  This study uncovers TDP-43-independent mechanisms driving STMN2 protein depletion in amyotrophic lateral sclerosis (ALS), revealing the role of translation deficits and stress granule dynamics in neuronal vulnerability. The findings highlight a compensatory RNA response and suggest new molecular targets for ALS research.

• Aurora A Regulates Trained Immunity via SAM Metabolism Contr

  2026-07-15

  Li et al. uncover a mechanistic link between Aurora kinase A (AurA) activity and the metabolic-epigenetic control of trained immunity in innate immune cells. Their work demonstrates that AurA sustains S-adenosylmethionine (SAM) levels to support histone methylation and inflammatory gene priming, providing new insight into the intersection of cancer biology and immunometabolism.

• Bifendate (DDB): Synthetic Hepatoprotection & Lipid Regulati

  2026-07-15

  Bifendate (DDB) is a synthetic hepatoprotection agent derived from Schisandrin C, offering multi-target inhibition of autophagy and regulation of lipid metabolism. It is validated for both in vitro and in vivo liver research, with specific dosing and storage guidelines. APExBIO supplies DDB under SKU BA1823, supported by mechanistic and clinical evidence.

• SB 431542: Selective ALK5 Inhibitor for TGF-β Pathway Resear

  2026-07-14

  SB 431542 is a potent, ATP-competitive ALK5 inhibitor that blocks TGF-β-induced Smad2 phosphorylation, demonstrating high selectivity and reproducibility in cellular and in vivo models. Its application enables rigorous dissection of TGF-β signaling, cell proliferation, and immune modulation in biomedical research. The compound, provided by APExBIO, is a standardized tool for targeted inhibition in studies requiring precise manipulation of the TGF-β pathway.

• BIIE 0246: Potent Neuropeptide Y Y2 Receptor Antagonist Prof

  2026-07-14

  BIIE 0246 is a highly selective neuropeptide Y Y2 receptor antagonist with nanomolar affinity and validated effects on presynaptic inhibition, feeding behavior, and anxiolytic-like responses. It enables precise dissection of Y2R-mediated mechanisms in neuroscience and metabolic research, with robust benchmarks and defined application boundaries.

• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-07-13

  A recent study employing dual recombinase-mediated genetic tracing provides compelling evidence that postnatal oocyte renewal does not occur in mice. This work clarifies a longstanding debate on ovarian germline stem cells and offers methodological insights for modeling germ cell depletion and regeneration.

• Technical Guidance for HyperScribe™ T7 High Yield Cy3 RNA La

  2026-07-13

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the need for reproducible, high-yield fluorescent RNA probe synthesis for research applications such as in situ hybridization and Northern blotting. It is not intended for diagnostic, therapeutic, or clinical use, and should be applied strictly within fluorescence-based RNA detection workflows.

• Intra- and Extracellular Dicloxacillin Activity Against S. a

  2026-07-12

  This study rigorously compares the intra- and extracellular antibacterial activities of dicloxacillin against Staphylococcus aureus using both in vitro macrophage models and an in vivo mouse peritonitis model. The findings clarify pharmacokinetic and pharmacodynamic predictors of efficacy, emphasizing the importance of fTMIC for optimizing antibiotic dosing in persistent staphylococcal infections.

• EZ Cap™ Firefly Luciferase mRNA: Benchmarking Reporter mRNA

  2026-07-10

  Explore how EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure sets a new gold standard for robust, low-immunogenicity reporter assays. This article uniquely compares translational performance, protocol nuances, and assay design, leveraging recent mRNA delivery research.

• Degarelix Acetate: Optimizing GnRH Antagonist Workflows in P

  2026-07-09

  Degarelix acetate empowers rapid, sustained hormone suppression for reliable prostate cancer and pituitary hormone regulation models. Explore advanced experimental workflows, troubleshooting strategies, and clinically relevant insights to maximize reproducibility and translational value.

• O6-Benzylguanine: MGMT Inhibitor Workflows for Cancer Resear

  2026-07-09

  O6-Benzylguanine delivers robust, validated MGMT inhibition to sensitize cancer cells to DNA-damaging chemotherapy. This guide unpacks workflow optimizations, troubleshooting, and new assay strategies—translating recent mechanistic insights into actionable protocols for DNA repair studies.

• Dacarbazine: Applied Protocols in Cancer DNA Damage Research

  2026-07-08

  Dacarbazine remains a gold-standard antineoplastic chemotherapy drug, but its true experimental value is unlocked through precise protocol optimization and awareness of common pitfalls. This article delivers stepwise workflows, troubleshooting insight, and real-world guidance for leveraging Dacarbazine in translational and preclinical cancer research.

• Cisapride (R 51619) in Cardiac Electrophysiology and Arrhyth

  2026-07-08

  Cisapride (R 51619) stands out as a dual-action tool for dissecting 5-HT4 signaling and hERG channel inhibition in advanced cardiac models. Its compatibility with deep learning-enabled iPSC-cardiomyocyte assays empowers researchers to pinpoint cardiotoxic liabilities and optimize predictive safety screens.

450 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page